Market Place
Sourcing Support
VISEN`s Palopegteriparatide Meets Endpoints In Phase 3 China Trial
12 Aug 2024 //
PR NEWSWIRE
VISEN Announces Acceptance of a BLA for Lonapegsomatropin in China
07 Mar 2024 //
PR NEWSWIRE
Double-blind period completes! Primary endpoint analysis of ph 3 clinical trial
06 Jan 2023 //
PR NEWSWIRE
VISEN Discloses 52-week Results for China Phase 3 Trial of Lonapegsomatropin
17 Nov 2022 //
PRNEWSWIRE
Positive Results from VISEN`s Phase 3 Trial of Once-Weekly TransCon hGH
23 May 2022 //
GLOBENEWSWIRE
VISEN Pharma`s Top-line Results of PIII Trial of Once-Weekly Lonapegsomatropin
23 May 2022 //
PRNEWSWIRE
The first hormone replacement therapy for hypoparathyroidism in China
03 Jun 2021 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.